Skip to main content

Molnupiravir and Sotrovimab

Question for Department of Health and Social Care

UIN HL728, tabled on 7 June 2022

To ask Her Majesty's Government what assessment they have made of whether their strategy to protect immuno-compromised individuals is over reliant on (1) second line treatments using Sotrovimab, and (2) fourth line treatments using Molnupiravir.

Answered on

21 June 2022

Recent evidence suggests that antivirals and neutralising monoclonal antibodies significantly improve clinical outcomes in non-hospitalised patients with COVID-19 who are at high risk of progression to severe disease. Available treatment options for eligible patients are the first line of nirmatrelvir/ritonavir or sotrovimab as clinically indicated; the second line of remdesivir; and the third line, molnupiravir.

These treatments have various safety profiles for patients with a range of characteristics, which ensures safe access. All patients are clinically assessed to ensure they receive the most appropriate treatment according to their health conditions. Therefore, there is no over reliance on one specific treatment path. The Antivirals and Therapeutics Taskforce is working with the RAPID C-19 Collaborative to review further COVID-19 treatments.